Unprecedented demand for GLP-1 receptor agonists has exposed capacity limits in peptide synthesis and specialized injection device manufacturing. Leading pharmaceutical firms are deploying record capital to secure proprietary production lines.
Contract Manufacturing Demand
Third-party contract development and manufacturing organizations are securing multi-year supply agreements. Facilities with sterile fill-finish capabilities are commanding premium valuations and long-term volume commitments.
Cost Dynamics and Access
Supply tightness continues to maintain high net pricing, impacting national health system budgets. Scale improvements are expected to ease wholesale price pressures over the next 36 months as new facilities attain regulatory clearance.